Tolerability, safety, pharmacokinetics and pharmacodynamics of SHR0534, a potent G protein-coupled receptor 40 (GPR40) agonist, at single- and multiple-ascending oral doses in healthy Chinese subjects

References

• Ackerson, T., et al., 2019. Mechanistic investigations of the liver toxicity of the free fatty acid receptor 1 agonist fasiglifam (TAK875) and its primary metabolites. Journal of biochemical and molecular toxicology, 33 (8), e22345.
   PubMed Web of Science ®Google Scholar
• Adler, A.I., et al., 1997. Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes care, 20 (7), 1162–1167.
   PubMed Web of Science ®Google Scholar
• Aharaz, A., et al., 2018. Risk of lactic acidosis in type 2 diabetes patients using metformin: A case control study. Plos one, 13 (5), e0196122.
   PubMed Web of Science ®Google Scholar
• Briscoe, C.P., et al., 2003. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. Journal of biological chemistry, 278 (13), 11303–11311.
   PubMed Web of Science ®Google Scholar
• Chen, X., et al., 2019. TAK-875 mitigates β-cell lipotoxicity-induced metaflammation damage through inhibiting the TLR4-NF-κB pathway. Journal of diabetes research, 2019, 5487962
   PubMed Web of Science ®Google Scholar
• Colhoun, H.M., et al.,; Scottish Diabetes Research Network Epidemiology Group. 2012. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia, 55 (11), 2929–2937.
   PubMed Web of Science ®Google Scholar
• DeFronzo, R.A., and Goodman, A.M., 1995. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. New England journal of medicine, 333 (9), 541–549.
   PubMed Web of Science ®Google Scholar
• Dormandy, J.A., et al.,; PROactive Investigators. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet (London, England), 366 (9493), 1279–1289.
   PubMed Web of Science ®Google Scholar
• Edfalk, S., Steneberg, P., and Edlund, H., 2008. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes, 57 (9), 2280–2287.
   PubMed Web of Science ®Google Scholar
• Fujihara, K., and Sone, H., 2018. Cardiovascular disease in japanese patients with type 2 diabetes mellitus. Annals of vascular diseases, 11 (1), 2–14.
   PubMed Web of Science ®Google Scholar
• Hauge, M., et al., 2015. GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo. Molecular metabolism, 4 (1), 3–14.
   PubMed Web of Science ®Google Scholar
• Hung, C.T., et al., 2020. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan. The journal of dermatology, 47 (3), 245–250.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation IDA 2019. 9th edition http://www.diabetesatlas.org.
   Google Scholar
• Itoh, Y., et al., 2003. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature, 422 (6928), 173–176.
   PubMed Web of Science ®Google Scholar
• Johnson-Rabbett, B., and Seaquist, E.R., 2019. Hypoglycemia in diabetes: The dark side of diabetes treatment. A patient-centered review. Journal of diabetes, 11 (9), 711–718.
   PubMed Web of Science ®Google Scholar
• Kahn, S.E., 2000. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. The American journal of medicine, 108 Suppl 6a, 2S–8S.
   PubMedGoogle Scholar
• Kaku, K., et al., 2015. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes, obesity and metabolism, 17 (7), 675–681.
   PubMed Web of Science ®Google Scholar
• Kalra, J., et al., 2020. SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy. Fundamental and clinical pharmacology, 34 (2), 173–188.
   PubMed Web of Science ®Google Scholar
• Klein, R., 1995. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes care, 18 (2), 258–268.
   PubMed Web of Science ®Google Scholar
• Li, Z., et al., 2018. Free fatty acid receptor 1 (FFAR1) as an emerging therapeutic target for type 2 diabetes mellitus: recent progress and prevailing challenges. Medicinal research reviews, 38 (2), 381–425.
   PubMed Web of Science ®Google Scholar
• Li, Z., Zhou, Z., and Zhang, L., 2020. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review. Expert opinion on therapeutic patents, 30 (1), 27–38.
   PubMed Web of Science ®Google Scholar
• Lu, C.J., et al., 2013. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. Cerebrovascular diseases (Basel, Switzerland)), 36 (2), 145–151.
   PubMed Web of Science ®Google Scholar
• Lv, W.S., et al., 2013. Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes. World journal of gastroenterology, 19 (20), 3134–3142.
   PubMed Web of Science ®Google Scholar
• MacKnight, C., et al., 2002. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dementia and geriatric cognitive disorders, 14 (2), 77–83.
   PubMed Web of Science ®Google Scholar
• Marcinak, J.F., et al., 2018. Liver safety of fasiglifam (TAK-875) in patients with type 2 diabetes: review of the global clinical trial experience. Drug safety, 41 (6), 625–640.
   PubMed Web of Science ®Google Scholar
• McGill, J.B., 2012. Pharmacotherapy in type 2 diabetes: a functional schema for drug classification. Current diabetes reviews, 8 (4), 257–267.
   PubMedGoogle Scholar
• Menon, V., et al., 2018. Fasiglifam-induced liver injury in patients with type 2 diabetes: results of a randomized controlled cardiovascular outcomes safety trial. Diabetes care, 41 (12), 2603–2609.
   PubMed Web of Science ®Google Scholar
• Molitch, M.E., et al., 2004. Nephropathy in diabetes. Diabetes care. 27, S79–S83.
   Google Scholar
• Nagasumi, K., et al., 2009. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes, 58 (5), 1067–1076.
   PubMed Web of Science ®Google Scholar
• Nanjan, M.J., et al., 2018. Thiazolidinediones as antidiabetic agents: A critical review. Bioorganic chemistry, 77, 548–567.
   PubMed Web of Science ®Google Scholar
• Otieno, M.A., et al., 2018. Fasiglifam (TAK-875): Mechanistic investigation and retrospective identification of hazards for drug induced liver injury. Toxicological sciences: an official journal of the society of toxicology, 163 (2), 374–384.
   PubMed Web of Science ®Google Scholar
• Ott, A., et al., 1999. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology, 53 (9), 1937–1942.
   PubMed Web of Science ®Google Scholar
• Panse, M., et al., 2015. Activation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) by free fatty acid receptor 1 (FFAR1/GPR40) protects from palmitate-induced beta cell death, but plays no role in insulin secretion. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology, 35 (4), 1537–1545.
   PubMedGoogle Scholar
• Pettitt, D.J., et al., 1980. Development of retinopathy and proteinuria in relation to plasma glucose cocentrations in pima indians. The lancet, 316 (8203), 1050–1052.
   Google Scholar
• Poitout, V., and Lin, D.C., 2013. Modulating GPR40: therapeutic promise and potential in diabetes. Drug discovery today, 18 (23-24), 1301–1308.
   PubMed Web of Science ®Google Scholar
• Rustenbeck, I., et al., 2004. Beta-cell toxicity of ATP-sensitive K + channel-blocking insulin secretagogues. Biochemical pharmacology, 67 (9), 1733–1741.
   PubMed Web of Science ®Google Scholar
• Sakuma, K., et al., 2016. Fasiglifam (TAK-875) has dual potentiating mechanisms via Gαq-GPR40/FFAR1 signaling branches on glucose-dependent insulin secretion. Pharmacology research and perspectives, 4 (3), e00237.
   PubMed Web of Science ®Google Scholar
• Sanchez-Rangel, E., and Inzucchi, S.E., 2017. Metformin: clinical use in type 2 diabetes. Diabetologia, 60 (9), 1586–1593.
   PubMed Web of Science ®Google Scholar
• Scheen, A.J., 2016. Investigational insulin secretagogues for type 2 diabetes. Expert opinion on investigational drugs, 25 (4), 405–422.
   PubMed Web of Science ®Google Scholar
• Schnell, S., Schaefer, M., and Schöfl, C., 2007. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Molecular and cellular endocrinology, 263 (1-2), 173–180.
   PubMed Web of Science ®Google Scholar
• Singh, S., 2014. Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy. Current diabetes reports, 14 (12), 563
   PubMed Web of Science ®Google Scholar
• Thule, P.M., and Umpierrez, G., 2014. Sulfonylureas: a new look at old therapy. Current diabetes report, 14, 473.
   PubMed Web of Science ®Google Scholar
• Tomita, T., et al., 2014. The G-protein-coupled long-chain fatty acid receptor GPR40 and glucose metabolism. Frontiers in endocrinology, 5, 152.
   PubMed Web of Science ®Google Scholar
• Wagner, R., et al., 2013. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Diabetes, 62 (6), 2106–2111.
   PubMed Web of Science ®Google Scholar
• Wild, S.H., et al.,; Scottish Diabetes Research Network Epidemiology Group. 2018. Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission. Diabetes care, 41 (2), 341–347.
   PubMed Web of Science ®Google Scholar
• Xu, W.L., et al., 2004. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology, 63 (7), 1181–1186.
   PubMed Web of Science ®Google Scholar
• Yabuki, C., et al., 2013. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. Plos one, 8 (10), e76280.
   PubMed Web of Science ®Google Scholar
• Yehya, A., and Sadhu, A.R., 2018. New therapeutic strategies for type 2 diabetes CME). Methodist debakey cardiovascular journal, 14 (4), 281–288.
   PubMedGoogle Scholar
• Younossi, Z.M., et al., 2004. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clinical gastroenterology and hepatology: the official clinical practice journal of the american gastroenterological association, 2 (3), 262–265.
   PubMed Web of Science ®Google Scholar